Company intelligence
evitria AG
FROM SEQUENCE TO ANTIBODY - 4 WEEKS - EXPRESSED IN CHO
Biotechnology Research
Zürich-Fahrweid, CH
33 employees
Founded 2010
1 public signals
About evitria AG
evitria is specialized in CHO-based transient expression of antibodies (including bispecific and fusion antibodies). With a track record of more than 120,000 successful antibody production runs for our clients, we can offer fast and reliable project execution at high quality standards (all production facilities in Switzerland). You can benefit from our expertise and unique focus when looking to entrust a partner with your complete antibody production or to manage capacity bottlenecks with single projects.
Verified activity
Signals from evitria AG
1 published signal